newsfilter
← Latest News
Business Wire·

Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Soci